Cargando…

WT1 peptide analogue WT1-126Y enhances leukemia lysis

Detalles Bibliográficos
Autores principales:	Alqudaihi, Ghofran, Lehe, Cynthia, Al-Alwan, Monther, Ghebeh, Hazem, Dickinson, Anne, Dermime, Said
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081985/ http://dx.doi.org/10.1186/2051-1426-2-S1-O3

Ejemplares similares

Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
por: Ghebeh, Hazem, et al.
Publicado: (2010)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Tumor suppressor function of WT1 in acute promyelocytic leukemia
por: Christopher, Matthew J., et al.
Publicado: (2021)

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
por: Liu, Hongtao, et al.
Publicado: (2018)

Editorial: WT1 in Development and Disease
por: Chau, You-Ying, et al.
Publicado: (2022)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

Microstructure and Hot Deformation Behavior of the Mg–8 wt.% Sn–1.5 wt.% Al Alloy
por: Sun, Zhaoqian, et al.
Publicado: (2021)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
por: Shirakawa, Toshiro, et al.
Publicado: (2017)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014)

Role for first zinc finger of WT1 in DNA sequence specificity: Denys–Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites
por: Wang, Dongxue, et al.
Publicado: (2018)

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation
por: Guo, Zhenzhen, et al.
Publicado: (2022)

Co-Precipitation, Strength and Electrical Resistivity of Cu–26 wt % Ag–0.1 wt % Fe Alloy
por: Li, Rui, et al.
Publicado: (2017)

WT1 regulates angiogenesis in Ewing Sarcoma
por: Katuri, Varalakshmi, et al.
Publicado: (2014)

Genomic Organization of the Human WT1 Gene
por: Tadokoro, Keiko, et al.
Publicado: (1992)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

A WT1-positive pleural neoplasm. Is it always a mesothelioma?: Diagnostic pitfall of WT1 immunohistochemistry in pleural neoplasm
por: Gaggero, G, et al.
Publicado: (2023)

An overlooked subset of Cx3cr1(wt/wt) microglia in the Cx3cr1(CreER-Eyfp/wt) mouse has a repopulation advantage over Cx3cr1(CreER-Eyfp/wt) microglia following microglial depletion
por: Zhou, Kai, et al.
Publicado: (2022)

A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation
por: Kaneko, Y, et al.
Publicado: (2015)

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)

Isolating $Wt$ production at the LHC
por: White, Chris D., et al.
Publicado: (2009)

Studies of Wilms’ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore
por: Lim, Che Kang, et al.
Publicado: (2007)

Prognostic Impact of WT-1 Gene Expression in Egyptian Children with Acute Lymphoblastic Leukemia
por: Hagag, Adel A, et al.
Publicado: (2016)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies
por: Suzuki, Mikito, et al.
Publicado: (2019)

Fabrication and wear behaviour of Mg-3wt.%Al-x wt. % SiC composites
por: Jayasathyakawin, S., et al.
Publicado: (2023)

Phase Stability of Dross Particles in Hot-Dip Zn-55wt%Al-1.6wt%Si Galvanizing Bath
por: Qu, Dongdong, et al.
Publicado: (2023)

PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis
por: Mansour, Fatmah A., et al.
Publicado: (2020)

WT1 Expression in the Human Fetus During Development
por: Ambu, R., et al.
Publicado: (2015)

The Wilms’ tumor (WT1) gene: Methods and protocols
por: Agrawal, Suraksha
Publicado: (2018)

Mutation Analysis of the WT1 Gene in Myelodysplastic Syndromes
por: Hosoya, Noriko, et al.
Publicado: (1998)

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

Wilms’ Tumour gene 1 (WT1) as an immunotherapeutic target
por: Coosemans, A.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_se5i0ucpe4hch0mqjg7kpqnka6